OSE Immunotherapeutics Stock Other OTC
Stocks
ORPOF
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded
| Market Cap | 93.84M 109M 86.37M 81.02M 152M 10.29B 154M 1.02B 399M 5.04B 409M 400M 17.44B | P/E Ratio 2026 * |
-3.07x | P/E Ratio 2027 * | -3.53x |
|---|---|---|---|---|---|
| Enterprise Value | 134M 155M 123M 115M 217M 14.66B 219M 1.45B 568M 7.18B 582M 570M 24.85B | EV / Sales 2026 * |
21.4x | EV / Sales 2027 * | 14.8x |
| Free-Float |
74.23% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: OSE Immunotherapeutics
| 1 day | -15.79% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 2025-10-01 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 2025-08-19 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 2021-12-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 2016-05-30 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 2017-06-13 |
| Director/Board Member | - | 2023-06-21 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -15.79% | -.--% | - | - | 109M | |
| +0.88% | +0.91% | -11.85% | -11.95% | 43.58B | |
| +4.02% | +7.79% | +294.33% | +536.67% | 34.03B | |
| -1.69% | -2.89% | +13.70% | -17.71% | 29.77B | |
| +1.41% | -0.96% | -0.53% | +33.41% | 29.82B | |
| +1.16% | +9.79% | +14.27% | +22.28% | 25.42B | |
| +2.40% | +8.49% | - | - | 13.87B | |
| +0.03% | +2.10% | +56.75% | +111.91% | 13.35B | |
| -0.95% | -3.39% | +2.51% | +2.08% | 12.85B | |
| +0.93% | +0.57% | +107.81% | +77.40% | 12.22B | |
| Average | -1.21% | +1.88% | +59.63% | +94.26% | 23.88B | |
| Weighted average by Cap. | +0.35% | +1.86% | +61.49% | +105.66% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.25M 7.25M 5.75M 5.4M 10.14M 685M 10.24M 68M 26.56M 336M 27.21M 26.64M 1.16B | 10.53M 12.22M 9.69M 9.09M 17.08M 1.15B 17.25M 115M 44.75M 565M 45.85M 44.88M 1.96B |
| Net income | -30.59M -35.49M -28.15M -26.41M -49.6M -3.35B -50.1M -333M -130M -1.64B -133M -130M -5.68B | -21.47M -24.91M -19.76M -18.53M -34.82M -2.35B -35.16M -234M -91.24M -1.15B -93.47M -91.49M -3.99B |
| Net Debt | 39.88M 46.27M 36.71M 34.43M 64.68M 4.37B 65.33M 434M 170M 2.14B 174M 170M 7.41B | 62.23M 72.2M 57.27M 53.73M 101M 6.82B 102M 677M 264M 3.34B 271M 265M 11.56B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
